Table 1.
Baseline demographic and clinical characteristics with virologic outcomes.
| Relapse | SVR | Total | ||
|---|---|---|---|---|
| Genotype 2 | Cirrhosis | 8 | 19 | 27 |
| No Cirrhosis | 6 | 20 | 26 | |
| Genotype 3 | Cirrhosis | 18 | 20 | 38 |
| No Cirrhosis | 21 | 19 | 40 | |
| Total | 53 | 78 | 131 | |
| Study | FISSION | 2 (2%) | ||
| POSITRON | 88 (67%) | |||
| FUSION | 41 (31%) | |||
| Treatment Duration | 12 weeks | 112 (85%) | ||
| 16 weeks | 19 (15%) | |||
| Race | AA | 10 (8%) | ||
| AI/AN | 2 (2%) | |||
| Asian | 5 (4%) | |||
| White | 114 (87%) | |||
| Ethnicity | Hispanic | 11 (8%) | ||
| Non-Hispanic | 120 (92%) | |||
| BMI | < 30 | 79 (60%) | ||
| ≤ 30 | 52 (40%) | |||
| IL28b Genotype | CC | 71 (54%) | ||
| CT | 43 (33%) | |||
| TT | 17 (13%) | |||
| ALT | < 1.5×ULN | 54 (41%) | ||
| ≥ 1.5×ULN | 77 (59%) | |||
| Age in years | 52.4 (10.1) | |||
| Plasma Log10HCV RNA (IU/ml) | 6.29 (0.82) | |||
| Creatinine Clearance in ml/min | 117.9 (33.5) | |||
Number and (Percentage) noted for all categorical variables
Mean and (SD) noted for all continuous variables
AA, African American; AI/AN, American Indian/Alaskan Native; ULN, upper limit of normal; HCV, Hepatitis C Virus; ALT, Alanine Aminotransferase; BMI, Body Mass Index; SVR, Sustained Virologic Response; GT2, genotype 2; GT3, genotype 3